The Experts below are selected from a list of 16863 Experts worldwide ranked by ideXlab platform
Peter J. Sadler - One of the best experts on this subject based on the ideXlab platform.
-
Advances in the design of Organometallic anticancer Complexes
Journal of Organometallic Chemistry, 2017Co-Authors: Pingyu Zhang, Peter J. SadlerAbstract:Abstract Organometallic Complexes containing ligands such as CO, carbenes, alkyls, phenyls, π-bound alkynes, alkenes, cyclopentadienyls and arenes possess properties which have often been exploited in areas such as catalysis and materials chemistry. They also offer opportunities for the design of new drugs with novel mechanisms of action. Here we focus on anticancer drugs which might complement successful platinum drugs in the clinic by widening the spectrum of activity, reducing side-effects and combatting resistance. The early clinical trials of titanocene dichloride highlighted the need to understand the aqueous solution chemistry of Organometallic Complexes and to identify their target sites in cancer cells. More recently Organometallic Cp Complexes of Fe(II), Rh(III) and Ir(III), and arene Complexes of Ru(II) and Os(II), have been shown to target the redox balance in cancer cells, in contrast to DNA which is the target of cisplatin and related platinum drugs. The activity of both catalytic and photoactive Organometallic compounds is being explored. Target recognition and activity are highly dependent not only on the metal and its oxidation state, but also the other coordinated ligands, the coordination number and geometry. In general, Organometallic Complexes are ‘pro-drugs’ which undergo activation in vivo (by ligand exchange or redox reactions), and the ligands themselves may be active components of the drug. A major challenge is to elucidate the chemistry of Organometallic Complexes directly in cells. The design of Organometallic Complexes for therapeutic and diagnostic applications in cancer and other areas of medicine present new and exciting research opportunities.
-
activation mechanisms for Organometallic anticancer Complexes
Medicinal Organometallic Chemistry, 2010Co-Authors: Ana M Pizarro, Abraha Habtemariam, Peter J. SadlerAbstract:Organometallic Complexes offer potential for design as anticancer drugs. They can act as inert scaffolds and specifically inhibit enzymes such as kinases, or as pro-drugs which undergo activation by various mechanisms. The activation of metallocenes, arene, alkyl or aryl Complexes by hydrolysis, and metal- or ligand-based redox reactions is discussed.
-
medicinal Organometallic chemistry designing metal arene Complexes as anticancer agents
Chemistry-an Asian Journal, 2008Co-Authors: Anna F A Peacock, Peter J. SadlerAbstract:The field of medicinal inorganic chemistry is rapidly advancing. In particular Organometallic Complexes have much potential as therapeutic and diagnostic agents. The carbon-bound and other ligands allow the thermodynamic and kinetic reactivity of the metal ion to be controlled and also provide a scaffold for functionalization. The establishment of structure-activity relationships and elucidation of the speciation of Complexes under conditions relevant to drug testing and formulation are crucial for the further development of promising medicinal applications of Organometallic Complexes. Specific examples involving the design of ruthenium and osmium arene Complexes as anticancer agents are discussed.
Kuo-hsiung Lee - One of the best experts on this subject based on the ideXlab platform.
-
one step templated synthesis of chiral Organometallic salicyloxazoline Complexes
Chemistry Central Journal, 2019Co-Authors: Mei Luo, Jing Cheng Zhang, Hao Yin, Cheng Ming Wang, Kuo-hsiung Lee, Susan L MorrisnatschkeAbstract:The general approach to the synthesis of metal Complexes begins with ligand synthesis, followed by ligand reaction with metal salts to afford Organometallic Complexes. Our research group first reported a one-pot multicomponent synthesis of chiral oxazolinyl–zinc Complexes, in the presence of a large amount of ZnCl2 (0.4–2.6 equiv.), with the yields of some products reaching 90%. Our prior strategy was extended to use copper, cobalt, nickel, manganese, palladium or platinum salts as the third component. The one-step method used 1.0 equivalent of a metal salt, such as M(OAc)2·nH2O or MCl2·nH2O (M: Cu, Co, Ni, Pd or Pt, n = 1, 2 or 4), as a reagent to generate chiral salicyloxazoline Complexes 1–8 in the reaction of 2-cyanophenol with different d- and l-amino alcohols. Complexes 1–8 were obtained using a one-pot method with a sequential strategy. The reaction outcome was demonstrated for three-component reactions between metal salts, amino alcohols and 2-hydroxybenzonitrile to afford Organometallic Complexes in good yields (65–95%).
-
One-step templated synthesis of chiral Organometallic salicyloxazoline Complexes
BMC, 2019Co-Authors: Mei Luo, Jing Cheng Zhang, Hao Yin, Cheng Ming Wang, Susan Morris-natschke, Kuo-hsiung LeeAbstract:Abstract Background The general approach to the synthesis of metal Complexes begins with ligand synthesis, followed by ligand reaction with metal salts to afford Organometallic Complexes. Our research group first reported a one-pot multicomponent synthesis of chiral oxazolinyl–zinc Complexes, in the presence of a large amount of ZnCl2 (0.4–2.6 equiv.), with the yields of some products reaching 90%. Results Our prior strategy was extended to use copper, cobalt, nickel, manganese, palladium or platinum salts as the third component. The one-step method used 1.0 equivalent of a metal salt, such as M(OAc)2·nH2O or MCl2·nH2O (M: Cu, Co, Ni, Pd or Pt, n = 1, 2 or 4), as a reagent to generate chiral salicyloxazoline Complexes 1–8 in the reaction of 2-cyanophenol with different d- and l-amino alcohols. Conclusion Complexes 1–8 were obtained using a one-pot method with a sequential strategy. The reaction outcome was demonstrated for three-component reactions between metal salts, amino alcohols and 2-hydroxybenzonitrile to afford Organometallic Complexes in good yields (65–95%)
Noel Lugan - One of the best experts on this subject based on the ideXlab platform.
-
manganese Organometallic compounds in homogeneous catalysis past present and prospects
Coordination Chemistry Reviews, 2016Co-Authors: Dmitry A Valyaev, Guy Lavigne, Noel LuganAbstract:Abstract The use of first row transition metal Complexes is one of the mainstreams in modern homogeneous catalysis. The case of manganese is peculiar in that catalytic applications of its coordination compounds featuring nitrogen- and oxygen-based ligands are well established, whereas those of its Organometallic Complexes exhibiting Mn C and/or Mn H bonds are still underdeveloped and have only recently focused substantial attention. The aim of the present report is to provide for the first time a comprehensive overview of this rapidly emerging area and to outline some prospects.
Annalisa Bisello - One of the best experts on this subject based on the ideXlab platform.
-
electronic communication in heterobinuclear Organometallic Complexes through unsaturated hydrocarbon bridges
Coordination Chemistry Reviews, 2004Co-Authors: Alberto Ceccon, Saverio Santi, Laura Orian, Annalisa BiselloAbstract:Abstract Much of the interest about the construction of model compounds suitable for investigating the phenomena associated with the interaction of two or more metal centers, the so-called cooperative effect, has been concentrated on homobimetallic Complexes and less attention has been paid to the class of heterobimetallic derivatives. This review will feature experimental detection and the effects of the electronic communication in heterobinuclear Organometallic Complexes through unsaturated hydrocarbon bridges. The described systems are classified according to the nature of the bridging ligand, in three main groups: (i) carbon σ-bonded molecular wires; (ii) fulvalene and fulvalene-like bridges; (iii) fused delocalized polycyclic bridges. In this contribution, we discuss the flexibility of heterobimetallic Complexes, and more in general of asymmetric bimetallic species, in terms of tailoring the cooperative effects, i.e. of controlling and tuning the reactivity of one metal center by acting on the adjacent one. Satisfactory quantitative estimate of the degree of metal to metal communication through the bridging ligand is obtained in illustrative examples combining efficient electrochemical and spectroscopic techniques with consolidated theories. A review with almost 350 references.
Gilles Gasser - One of the best experts on this subject based on the ideXlab platform.
-
underestimated potential of Organometallic rhenium Complexes as anticancer agents
ACS Chemical Biology, 2014Co-Authors: Anna Leonidova, Gilles GasserAbstract:In the recent years, Organometallic compounds have become recognized as promising anti-cancer drug candidates. While radioactive 186/188Re compounds are already used in clinics for cancer treatment, cold Re Organometallic compounds have mostly been explored as luminescent probes for cell imaging and photosensitizers in photocatalysis. However, a growing number of studies have recently revealed the potential of Re Organometallic Complexes as anti-cancer agents. Several compounds have displayed cytotoxicity equaling or exceeding that of the well-established anti-cancer drug cisplatin. In this review, we present the currently known Re Organometallic Complexes that have shown anti-proliferative activity on cancer cell lines. A particular emphasis is placed on their cellular uptake and localization as well as their potential mechanism of action.
-
the potential of Organometallic Complexes in medicinal chemistry
Current Opinion in Chemical Biology, 2012Co-Authors: Gilles Gasser, Nils MetzlernolteAbstract:Organometallic Complexes have unique physico-chemical properties, which have been widely used in homogenous catalysis, for example, for the synthesis of lead compounds and drug candidates. Over the past two decades, a few scientists from all over the world have extended the use of the specific characteristics of these compounds (e.g. structural diversity, possibility of ligand exchange, redox and catalytic properties) for medicinal purposes. The results are stunning. A few Organometallic compounds have already entered clinical trials and it can be anticipated that several more will follow in coming years. In this short review, we present the specific advantages that Organometallic metal Complexes have over purely organic and also coordination compounds. Furthermore, using specific examples, we illustrate how these particular properties can be put to good use in medicinal chemistry. The examples we present have an emphasis on, but are not restricted to, anti-cancer activity.
